Aratana, a US-based biopharmaceutical company developing medicines for cats and dogs, plans to float 4.25 million shares at between $11 and $13 each.
The pre-revenue company has raised over $30m in VC funding. Shareholders include MPM Ventures (24.97% pre-IPO stake), Avalon Ventures (23.78%), Cultivian Ventures (8.62%) and RaQualia Pharma (11.43%), which provides clinical and pre-clinical candidates for human patients.
Aratana plans to trade on the Nasdaq under ticker symbol PETX, with investment banks Stifel and Lazard serving as lead underwriters.